Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Pfizer CEO Albert Bourla told CBS News' "Face the Nation" Sunday that his company will know whether its coronavirus vaccine is effective by the end of October and that it has already manufactured hundreds of thousands of doses in anticipation that the vaccine will receive FDA approval.

Why it matters: There has been a major push by the Trump administration to get a coronavirus vaccine to the public this fall, though it may only be available for certain high-risk groups. The Centers for Disease Control and Prevention has already urged governors to have vaccine distribution centers ready by November.

Yes, but: 62% of adults say they're worried the FDA will rush to approve a vaccine under political pressure from President Trump, according to a poll by the Kaiser Family Foundation.

  • Politico reported on Friday that Trump-appointed health department aides interfered with the CDC’s weekly COVID-19 reports “in what officials characterized as an attempt to intimidate the reports’ authors and water down their communications to health professionals."
  • Only 14% of Americans think a coronavirus vaccine will be widely available before the November election, and even if it is, most Americans say they won't take it.

Go deeper: AstraZeneca to resume COVID-19 vaccine trials

Go deeper

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Health: CDC director warns "now is not the time" to lift COVID restrictions — Exclusive: Teenagers' mental health claims doubled last spring.
  2. Axios-Ipsos poll: Americans' hopes rise after a year of COVID
  3. Vaccine: J&J CEO "absolutely" confident in vaccine distribution goals — Vaccine hesitancy is shrinking.
  4. World: China and Russia vaccinate the world, for now.
  5. Energy: Global carbon emissions rebound to pre-COVID levels.
  6. Local: Florida gets more good vaccine newsMinnesota's hunger problem grows amid pandemic — Denver's fitness industry eyes a pandemic recovery.
Dec 21, 2020 - Health

The coronavirus mutation in the U.K.: What you need to know

Moncef Slaoui, chief science adviser for Operation Warp Speed. Photo: Mandel Ngan/AFP via Getty Images

Researchers are closely watching whether a newly discovered mutation in the SARS-CoV-2 virus is cause for alarm as parts of Europe limited international travel this week.

Why it matters: Despite the variant appearing to be more transmissible, U.S. officials stressed in a call today that it's no more deadly and the chances it will make vaccines less effective are "extremely low."

Updated Dec 21, 2020 - World

EU grants approval to Pfizer-BioNTech vaccine

Photo: JOEL SAGET/AFP via Getty Images

The European Commission on Monday granted market authorization to Pfizer-BioNTech's COVID-19 vaccine, hours after the European Medicines Agency (EMA) recommended approval.

Why it matters: European Commission President Ursula von der Leyen said that vaccinations will begin in the EU's 27 countries on Dec. 27, 28 and 29. The vaccine has been found to be 95% effective with no serious side effects.